Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow dips below year-ago levels
Q3 FY2026 financing cash flow of $126.77M fell 25.4% year over year, behind the +390.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 80.9% from the prior quarter.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -25.4% toward the trailing-twelve-month pace of +390.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 170.32M USD
- Year-over-year change
- -62.1%
- 5-year CAGR
- +28.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 170.32M | -62.1% |
| FY2024 | 2024-12-31 | 449.54M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 23.09M | -52.3% |
| FY2020 | 2020-12-31 | 48.45M | — |
Financing Cash Flow vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 financing cash flow of $830.71M is the 2nd largest of the 10 companies compared; the peer median is $103.52M.
- Its year-over-year change of +390.1% is the 2nd highest of 10, against a peer median of +40.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.03B | +2428.7% | +42.6% | 54053.9% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $830.71M | +390.1% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M | +53.0% | -72.7% | 4878.8% |
| FY2025 | $142.01M | +71.6% | — | 10519.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | $127.78M | +11.1% | — | — |
| LTM Mar 2026 | $103.52M | +40.9% | +6.8% | — | |
| LTM Mar 2026 | $102.81M | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $52.19M | -29.8% | — | 623.8% | |
| LTM Jun 2026 | $8.3M | -95.9% | +13.0% | 7.9% | |
| FY2025 | $1.09M | +381.5% | — | 1707.8% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $103.52M | +40.9% | +9.9% | 1707.8% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.74M) | (19.32M) | (9.93M) | (83.72M) | (105.43M) |
| Depreciation & Amortization | 93K | 91K | 114K | 27K | 83K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.88M | (28K) | (1.66M) | 11.59M | (2.56M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.1M | (411K) | (783K) | 3.46M | 693K |
| Other Working Capital | 776K | 383K | (878K) | 8.13M | (3.25M) |
| Other Non-Cash Items | 43K | 497K | 561K | 14.27M | 19.7M |
| Operating Cash Flow | (7.73M) | (18.76M) | (10.91M) | (57.84M) | (88.21M) |
| Capital Expenditures | (19K) | (43K) | (2K) | (189K) | (209K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (329.94M) | (520.96M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 424.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (19K) | (43K) | (2K) | (330.13M) | (96.75M) |
| Debt Repayment | (408K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 48.86M | 23.09M | 0 | 449.54M | 170.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 48.45M | 23.09M | 0 | 449.54M | 170.32M |
| Effect of Forex Changes | 0 | 0 | 0 | (37.43M) | 0 |
| Net Change in Cash | 40.71M | 4.29M | (10.91M) | 24.14M | (14.64M) |
| Free Cash Flow | (7.74M) | (18.81M) | (10.91M) | (58.03M) | (88.42M) |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.